Findings from Peking University Provides New Data on Adenocarcinoma (First-line Cadonilimab Plus Chemotherapy In Her2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Randomized, Double-blind, Phase 3 Trial)